Neoadjuvant therapy versus upfront resection for clinically “resectable” pancreatic cancer: The debate continues
We have assembled two articles addressing factors predictive of early recurrence (within 6 months postoperatively) after curative resection of clinically resectable pancreatic ductal cancer (PDAC) and after clinically resectable invasive intraductal papillary mucinous neoplasm. Although many, if not most, pancreatic surgeons accept the importance of neoadjuvant therapy for borderline resectable PDAC, the concept of neoadjuvant therapy for clinically resectable PDAC or invasive intraductal papillary mucinous neoplasm is not yet universally accepted.
Source: Surgery - Category: Surgery Authors: Michael G. Sarr, Kevin E. Behrns Source Type: research
More News: Borderline Mucinous Tumor | Cancer | Cancer & Oncology | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Surgery